Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;19(1):15-33.
doi: 10.1002/wps.20693.

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

Affiliations

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

Robert A McCutcheon et al. World Psychiatry. 2020 Feb.

Abstract

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both have been proposed to contribute significantly to the pathophysiology of schizophrenia. In this paper we assess research that has implicated both systems in the aetiology of this disorder. We examine evidence from post-mortem, preclinical, pharmacological and in vivo neuroimaging studies. Pharmacological and preclinical studies implicate both systems, and in vivo imaging of the dopamine system has consistently identified elevated striatal dopamine synthesis and release capacity in schizophrenia. Imaging of the glutamate system and other aspects of research on the dopamine system have produced less consistent findings, potentially due to methodological limitations and the heterogeneity of the disorder. Converging evidence indicates that genetic and environmental risk factors for schizophrenia underlie disruption of glutamatergic and dopaminergic function. However, while genetic influences may directly underlie glutamatergic dysfunction, few genetic risk variants directly implicate the dopamine system, indicating that aberrant dopamine signalling is likely to be predominantly due to other factors. We discuss the neural circuits through which the two systems interact, and how their disruption may cause psychotic symptoms. We also discuss mechanisms through which existing treatments operate, and how recent research has highlighted opportunities for the development of novel pharmacological therapies. Finally, we consider outstanding questions for the field, including what remains unknown regarding the nature of glutamate and dopamine function in schizophrenia, and what needs to be achieved to make progress in developing new treatments.

Keywords: D1 receptors; D2 receptors; GABA interneurons; NMDA receptors; Psychosis; amphetamine; antipsychotics; cognitive symptoms; dopamine; dorsolateral prefrontal cortex; glutamate; ketamine; schizophrenia; striatum.

PubMed Disclaimer

References

    1. McCutcheon RA, Marques TR, Howes OD. Schizophrenia: an overview. JAMA Psychiatry (in press). - PubMed
    1. Hjorthøj C, Stürup AE, McGrath JJ et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta‐analysis. Lancet Psychiatry 2017;4:295‐301. - PubMed
    1. van Rossum JM. The significance of dopamine‐receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Thérapie 1966;160:492‐4. - PubMed
    1. Kaar SJ, Natesan S, McCutcheon R et al. Antipsychotics: mechanisms underlying clinical response and side‐effects and novel treatment approaches based on pathophysiology. Neuropharmacology (in press). - PubMed
    1. Carlsson A, Lindqvist M, Magnusson T. 3,4‐Dihydroxyphenylalanine and 5‐hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200. - PubMed